Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine... see more

NDAQ:PMN - Post Discussion

ProMIS Neurosciences Inc > Reverse Splits No Value
View:
Post by TopBroker on Jul 06, 2021 9:37pm

Reverse Splits No Value

Reverse splits only delay the inevitable: decline, delisting, and becoming destitute. A company's fundamentals have in no way improved, despite a share price that's 20 times higher than it was pre-reverse-split. If the company is still troubled, a reverse split just gives the share price a higher roof to plunge from.

But i better defer to that savy investor David the King who does not have one client.
Comment by Thenorth1990 on Jul 06, 2021 10:11pm
Tb you are right but if it helps this company gets Nasdaq listing where it should attract much more investors won't that be in company's favor.? I am personally against reverse split. Few of the companies I had watched went through this and nothing changed for them.
Comment by DavidKingCanada on Jul 06, 2021 10:51pm
Well this is my point but it seems everyone is complaining about Dilution and when I bring up the idea of any sort of Consolidation I get bombarded. 
Comment by Thenorth1990 on Jul 06, 2021 10:58pm
Pre clinical small cap stage company means reverse split and name change is unavoidable, I am sure everyone knows that and people on the board are much more experienced . I looked up Eli lilly since 1986 they have gone through 4 splits, its also a survival mechanism to stay relevant and not a penny stock . Now there is a different side of the story , most of them have achieved 4000% returns in 20 ...more  
Comment by Speyeder999 on Jul 07, 2021 10:03am
I apologize in advance for repeating myself, but doesn't a reverse spilt (share consolidation) have to be approved by the board at an AGM for it to materialize in the given year?  TB, isn't this up your alley?
Comment by farmerjane on Jul 07, 2021 10:14am
Need News badly, talk of reverse splits, Nasdaq, is nonsense !!
Comment by M101 on Jul 07, 2021 1:06pm
    You could say that every summer, but this is the first time we won't run out of money in time for a tax-loss sale, and without the constant pressure to churn new stock for warrants we might hold this valuation until real news happens. Last year our churners took over in mid July, if this year is different it will be obvious by the end of the month. 
Comment by Thenorth1990 on Jul 07, 2021 6:04pm
Aducanumab approval was also non sense until June 7. Anyways I hope everyone wins.
Comment by DavidKingCanada on Jul 07, 2021 7:08pm
Yep, exactly! 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities